Nuvalent, Inc.
NUVL
Clasificación en acciones
#2113
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Precio por acción
$123.96
Última sincronización: 2026-07-21
Capitalización bursátil
$9.75B
Cambio (1 día)
0.00%
Cambio (1 año)
27.56%
País
US
Comercio Nuvalent, Inc. (NUVL)
Categoría
Healthcare
Número de acciones en circulación de Nuvalent, Inc. (NUVL)
Número de acciones en circulación al March 2026: 78.67M
Según los últimos informes financieros y el precio de las acciones de Nuvalent, Inc., el número actual de acciones en circulación es 78.67M. Al final de December 2023, la empresa tenía 58.22M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Nuvalent, Inc. (NUVL) desde 2019 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 78.67M | 18.46% |
| 2024 | 66.41M | 14.06% |
| 2023 | 58.22M | 17.22% |
| 2022 | 49.67M | 128.02% |
| 2021 | 21.78M | -4.73% |
| 2020 | 22.86M | -52.65% |
| 2019 | 48.28M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 222.74% |
US
|
|
| 396.00M | 403.37% |
US
|
|
| 478.91M | 508.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.95% |
NL
|
